Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Sanofi Shares Slide After Trials of Potential Breast Cancer Drug Halted

Published 2022/08/17, 15:12
ROG
-
SASY
-
AZN
-
SNY
-
RHHVF
-
AVEPp
-

By Scott Kanowsky 

Investing.com -- Sanofi SA (EPA:SASY) shares slid on Wednesday after the French drugmaker announced that it will halt trials of a new treatment for patients battling advanced breast cancer.

In a statement, the company said it would stop global clinical development of the medicine, known as amcenestrant, after a phase 3 study showed it was not effective enough to warrant further research.

All other studies of amcenestrant, including in early-stage breast cancer, will also be discontinued, Sanofi added.

“While we are disappointed by this outcome, our research will further the scientific understanding of endocrine therapies in people with breast cancer," said John Reed, global head of research and development at Sanofi.

In a note, analysts at Morgan Stanley called the decision a "setback for the innovation narrative" put forward by Sanofi, saying that amcenestrant had been flagged as a potentially lucrative piece in the group's drug pipeline.

The end of Sanofi's amcenestrant trials is expected to lead to a 6% negative impact on the company's estimated discounted cash flow, according to the Morgan Stanley analysts.

The decision could also have a knock-on effect on studies being conducted on similar breast cancer drugs from Sanofi rivals Roche (SIX:ROG) and AstraZeneca PLC (LON:AZN), the analysts added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.